Related Experiment Video
Updated: Mar 26, 2026

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
Published on: March 25, 2016
[Ibrutinib prescription in B-cell lymphoid neoplasms]
Aurore Dougé1, Aurélie Ravinet1, Jacques-Olivier Bay1
1CHU de Clermont-Ferrand, service d'hématologie clinique adulte et de thérapie cellulaire, 63003 Clermont-Ferrand, France; Clermont université, université d'Auvergne, EA7283, CIC501, BP 10448, 63000 Clermont-Ferrand, France.
Abstract:
Ibrutinib is a new-targeted therapy that irreversibly and specifically inhibits the Bruton's Tyrosine Kinase (BTK), a key component of the signaling pathways of B cells. The results are very encouraging as monotherapy in the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenström's macroglobulinemia. Following the results of recent studies, ibrutinib is now available in France for these three diseases.
Related Concept Videos
Treatment Resistent Cancers
Treatment Resistant Cancers
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Targeted Cancer Therapies
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

